GENESIS-PHARMA
12.1.2024 12:37:29 CET | Business Wire | Press release
GENESIS Pharma, a leading regional biopharma company operating in Europe, and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, announce an exclusive distribution agreement for RIPRETINIB in 14 European markets in Central and Eastern Europe. Under the terms of the agreement, GENESIS Pharma will exclusively commercialize RIPRETINIB for the treatment of fourth-line gastrointestinal stromal tumor (GIST) in: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia, and Slovenia.
RIPRETINIB is approved in the European Union for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
Ms. Margarida Duarte, Senior Vice President, Head of International, Deciphera Pharmaceuticals stated: “We are excited to partner with GENESIS Pharma to distribute RIPRETINIB across Central and Eastern Europe, ensuring fourth-line GIST patients in these countries have access to this standard-of-care treatment. Deciphera is committed to commercializing RIPRETINIB globally, and our agreement with GENESIS Pharma builds upon the significant progress we have already made launching the therapy in Europe, positioning us well for continued growth as we work together to improve the lives of GIST patients”.
Mr. Constantinos Evripides, Managing Director of GENESIS Pharma stated: “We are pleased to expand the network of our international partners and honored that Deciphera recognized our expertise and track record in the commercialization of innovative biopharmaceutical products targeting severe and rare diseases. This agreement is an important step forward in expanding our geographical reach and delivering our mission to ensure that such products are made available to patients in the countries we operate. We look forward to joining forces with Deciphera to enable access to this important innovative therapy for eligible patients in Central and Eastern Europe”.
About Gastrointestinal stromal tumor (GIST)
Gastrointestinal stromal tumor (GIST) is a rare neoplasm of the gastrointestinal tract affecting the digestive tract or nearby structures within the abdomen, most often presenting in the stomach or small intestine1. GIST is the most frequent sarcoma of the gastrointestinal tract, with a reported incidence of 10-15 cases per million per year2. The majority of GISTs are driven by two oncogenic protein kinases, KIT and PDGFRA gain-of-function mutations. The most common primary mutations are in KIT kinase, representing approximately 80% of cases, or in PDGFRA kinase, representing approximately 5-10% of cases3. Current therapies are unable to inhibit the full spectrum of primary and secondary mutations, which drives resistance to most tyrosine kinase inhibitors (TKIs) therefore leading to disease progression4. Estimates for 5-year survival rate range from 48% to 90%, depending on the stage of the disease at diagnosis5.
About Deciphera
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, RIPRETINIB is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. RIPRETINIB is approved in Australia, Canada, China, the European Union, Hong Kong, Iceland, Israel, Liechtenstein, Macau, New Zealand, Singapore, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and X (@Deciphera).
About GENESIS Pharma
GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative biopharmaceutical products targeting severe and rare diseases in Central and Eastern Europe. Established in 1997, GENESIS Pharma was among the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products. GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical need through long standing strategic alliances with some of the leading global biopharma companies. For more information, please visit www.genesispharmagroup.com.
1. Parab TM, DeRogatis MJ, Boaz AM, Grasso SA, Issack PS, Duarte DA, Urayeneza O, Vahdat S, Qiao JH, Hinika GS. Gastrointestinal stromal tumors: a comprehensive review. J Gastrointest Oncol. 2019 Feb;10(1):144-154.
2. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol. 2016 Feb;40:39-46.
3. Lostes-Bardaji MJ, García-Illescas D, Valverde C, Serrano C. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986498.
4. Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, DiNitto JP, English JM, Greig MJ, He YA, Jacques SL, Lunney EA, McTigue M, Molina D, Quenzer T, Wells PA, Yu X, Zhang Y, Zou A, Emmett MR, Marshall AG, Zhang HM, Demetri GD. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1542-7.
5. American Cancer Society. (March 1, 2023). Gastrointestinal stromal tumor survival rates. Retrieved December 21, 2023, from https://www.cancer.org/cancer/types/gastrointestinal-stromal-tumor/detection-diagnosis-staging/survival-rates.html.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240111379909/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Reveals 265% ROI and 99.99% Reduction in Risk of Exposure to Addressable Breach Risk Costs According to Total Economic Impact Study3.2.2026 15:00:00 CET | Press release
Effectiveness of Yubico’s technology: $5.3 million Net Present Value and $7.3 million in total benefits over three years, driven by 80% faster authentication and reduced help desk burden Yubico (NASDAQ STOCKHOLM: YUBICO), a modern cybersecurity company and creator of the most secure passkeys, today announced the results of a commissioned Total Economic Impact™ (TEI) of Yubico YubiKeys study conducted by Forrester Consulting. The study, comprised of interviews with global enterprises with over 5,000 employees, found that a composite organization based on interviewed customers achieved a 265% return on investment (ROI) and a net present value (NPV) of $5.3 million over three years by replacing traditional multi-factor authentication (MFA) and one-time passwords (OTPs) with phishing-resistant YubiKeys. In an era of high-quality deepfakes and generative AI-driven extortion, the study shows a critical shift in cybersecurity: traditional MFA is no longer sufficient to stop modern MFA-bypass
Fitch Solutions Delivers AI-Ready Credit Data on Snowflake Marketplace3.2.2026 15:00:00 CET | Press release
Direct access to Fitch Ratings and dv01 datasets now available on Snowflake Marketplace to accelerate financial modeling Fitch Solutions, a leading global provider of insights, data, and analytics, today announced a collaboration with Snowflake, the AI Data Cloud company, to deliver Fitch’s comprehensive datasets on Snowflake Marketplace. This offering will enable market participants and clients to access and work with Fitch’s credit intelligence directly within Snowflake, supporting faster analysis and simpler integration across modern workflows. Fitch Ratings credit data and loan-level performance benchmark datasets from dv01, a Fitch Solutions company, covering the U.S. auto, consumer unsecured, and non-agency RMBS sectors, are now available on Snowflake Marketplace. Additional offerings will follow, including data from Sustainable Fitch, CreditSights, and BMI. Over time, this will enable clients to access all of Fitch Solutions' universe directly in Snowflake. “Data sits at the hea
SLB Awarded Integrated Development Contract for Mutriba Field in Kuwait3.2.2026 15:00:00 CET | Press release
Kuwait Oil Company awards SLB five-year contract for next stage of Mutriba field development Global technology company SLB (NYSE: SLB) today announced that Kuwait Oil Company has awarded SLB a $1.5 billion, five-year integrated contract for the Mutriba field in Kuwait, including design, development and production management. The work builds on SLB’s subsurface understanding of the Mutriba field to support development planning and execution across deeper, technically demanding reservoir conditions. The contract covers development of high-pressure, high-temperature reservoirs with sour conditions, reflecting an expanded scope and responsibility for SLB as work on the Mutriba field progresses. “This award reflects the strength of our long-standing partnership with Kuwait Oil Company and the trust built over decades of working together,” said Steve Gassen, executive vice president, Geographies, SLB. “As development of the Mutriba field moves into its next stage, we are taking on end-to-end
LF Chooses Rimini Street to Optimize ERP Support, Drive Innovation and Transform the Business3.2.2026 15:00:00 CET | Press release
Leading South Korean lifestyle brand turns to Rimini Support™ for its Oracle and SAP enterprise systems to achieve cost savings, improve quality and responsiveness and fund innovation Rimini Street, Inc., (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced that LF, a leading lifestyle company in South Korea, has selected Rimini Support™ to optimize maintenance for SAP ECC 6.0 and Oracle Database systems. With Rimini Street, LF is enhancing operational stability and accelerating business innovation projects, leveraging cost savings achieved to fuel transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203604473/en/ LF Chooses Rimini Street to Optimize ERP Support, Drive Innovation and Transform the Business LF’s Journey to Premium Support for Less Founded in 1974, LF is a leader in South Korea’s fashion
CSG Helps Businesses Cut Fraud Losses by Up to 70% with CSG Payments Protection.ai3.2.2026 14:30:00 CET | Press release
AI-powered fraud detection solution enables near-real-time, cross-channel transaction monitoring to stop fraud without slowing legitimate payments As payments fraud accelerates with AI, businesses are racing to spot and block threats without slowing customers down. Today, CSG® (NASDAQ: CSGS) launched CSG Payments Protection.ai, a next-generation fraud detection and financial risk management solution to accurately identify and stop payment fraud. The solution proactively monitors digital transactions across diverse payment channels and fraud types, so businesses can reduce fraud losses by 50–70% while significantly lowering false-positive alerts and the resulting customer friction. “Fraud is no longer a once-in-a-while surprise,” said Saurabh Joshi, EVP and President, CSG Payments. “It’s constant, adaptive, and affects businesses regardless of size or industry. That’s why it was so important for us to offer an always‑learning AI solution that can help businesses stay ahead of increasing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom